Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 9/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6727845 | 0.86 | GRM2 (0.45) | GRM2KMT2ALMNAGAATSHR | |
| SCHEMBL6731093 | 0.85 | GRM2 (0.52) | GRM2KMT2ASMN1; SMN2 | |
| SCHEMBL6727871 | 0.84 | GRM2 (0.40) | GRM2SMN1; SMN2TRPM8 | |
| SCHEMBL6732387 | 0.83 | GRM2 (0.47) | GRM2TRPM8 | |
| SCHEMBL6731207 | 0.83 | GRM2 (0.41) | GRM2KMT2A | |
| SCHEMBL6732565 | 0.82 | GRM2 (0.46) | GRM2GAATRPM8 | |
| SCHEMBL6733359 | 0.82 | GRM2 (0.57) | GRM2 | |
| SCHEMBL6768436 | 0.82 | GRM2 (0.54) | GRM2LMNAGAATSHRHTT | |
| SCHEMBL6739586 | 0.82 | GRM2 (0.69) | GRM2LMNAGAATSHRHTT | |
| SCHEMBL6731292 | 0.80 | GRM2 (0.57) | GRM2LMNAGAATSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040006114-A1 | Potentiators of glutamate receptors | ELI LILLY AND COMPANY | 2004-01-08 | — | — | US | claimed |
| EP-1255735-A2 | PYRIDINE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2002-11-13 | — | — | EP | claimed |
| WO-2001056990-A2 | PYRIDINE DERIVATES AS POTENTIATORS OF GLUTAMATE RECEPTORS | ELI LILLY AND COMPANY (US) | 2001-08-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006114-A1 | Potentiators of glutamate receptors | GRM1, GRIN1, GRM2 | GRM2 3/4885KMT2A 3440/4885LMNA 4863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.